anti-GUCY2C CAR T-cell therapy (Parasol Biotechnology/Anhui provincial cancer hospital)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-GUCY2C CAR T-cell therapy (Parasol Biotechnology/Anhui provincial cancer hospital)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionHeat-stable enterotoxin receptor modulators
TargetsHeat-stable enterotoxin receptor
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHeFei Parasol Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAnhui Cancer HospitalHeFei Parasol Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A